All CRC tumors had at least one mutation with an AF‰ ≥ 0.1, and 96.7% of them presented at least one mutation with AF‰ ≥ 1 in any of the four genes investigated; the KRAS G12/G13 was the most prevalent mutation detected in our cohort, followed by NRAS G12/G13 (25%, AF‰ ≥ 1) and KRAS Q61 (21.7%, AF‰ ≥ 1) (Table 1). This evidence concerns the gene KRAS and colorectal carcinoma.